WO2022098366A1

WO2022098366A1 - Skincare compositions for preventing transepidermal water loss

Info

Publication number: WO2022098366A1
Application number: PCT/US2020/059637
Authority: WO
Inventors: Susan Syto GOLDSBERRY; Lyndon Syto GARCINES; Jennifer D. EWING
Original assignee: Redwood Ip Holding, Llc
Priority date: 2020-11-09
Filing date: 2020-11-09
Publication date: 2022-05-12

Abstract

The present invention provides skincare compositions for reducing and/or preventing transepidermal water loss. These skincare compositions contain ceramides, Helianthus Annuus (sunflower) seed oil, Inula Helenium (elecampane root) extract, bisabolol and Zingiber Officinale (Ginger) root extract, squalane, and hyaluronic acid as well as other optional ingredients including a cannabinoid. The invention also provides for use of these compositions to reduce and/or prevent transepidermal water loss or to treat diseases associated with transepidermal water loss, such as, atopic dermatitis, contact dermatitis, psoriasis, and/or ichthyosis.

Description

SKINCARE COMPOSITIONS FOR PREVENTING TRANSEPIDERMAL WATER LOSS

TECHNICAL FIELD

[0001] This application relates to skincare compositions that are specifically designed to minimize, reduce, and/or prevent transepidermal water loss.

BACKGROUND OF THE INVENTION

[0002] Transepidermal water loss (“TEWL”) is the amount of water that passively evaporates through skin to the external environment due to water vapor pressure gradient on both sides of the skin barrier and is used to characterize skin barrier function. Golara Honari, Howard Maibach, in Applied Dermatotoxicology, 2014. TEWL occurs naturally when the outermost layer of skin, the epidermis, loses water to the surrounding air through evaporation.

[0003] When water evaporates faster than the body can replace it, the skin becomes dehydrated, which can lead to irritated, rough, and/or itchy skin that can crack and cause discomfort. Dry skin also appears more aged, and fine lines as well as wrinkles are accentuated. Once the skin shows signs of dryness, TEWL accelerates even further as the barrier of the skin function is further limited.

[0004] Transepidermal water loss has been known to contribute to a variety of unwanted skin conditions, including a more prominent appearance of fine lines and wrinkles. Transepidermal water loss has also been associated with a variety of dermatological conditions. “Skin diseases in which the skin barrier is disturbed, such as atopic dermatitis (AD), contact dermatitis, psoriasis, and ichthyosis, are associated with elevated TEWL.” Alexander et al., Journal of Investigative Dermatology, 138, 2295-2300 at 2296 (2018). “Psoriasis is a dermatosis with overall compromise of the skin barrier function exhibiting exponential TEWL in lesional skin, with increased TEWL over non- lesional skin as well.” Nikam et al., Indian Dermatology Online Journal 10(3):267 (2019).

[0005] Accordingly, what is needed is an uncomplicated way to reduce transepidermal water loss. The instant disclosure provides skincare compositions that are topically applied to reduce transepidermal water loss. SUMMARY OF THE INVENTION

[0006] This application provides skincare compositions for reducing, and/or preventing transepidermal water loss and use of those compositions in methods of reducing or preventing transepidermal water loss. These skincare compositions contain at least: (a) one or more Ceramide; (b) Helianthus Annuus (sunflower) seed oil; (c) Inula Helenium (elecampane root) extract; (d) bisabolol and Zingiber Officinale (Ginger) root extract; (e) squalane; and (f) hyaluronic acid. The compositions may have a pH between about 5.00 to about 6.5.

[0007] In one embodiment, the skincare composition contains: (a) at least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, or Ceramide EOS; (b) Helianthus Annuus (sunflower) seed oil; (c) Inula Helenium (elecampane root) extract; (d) bisabolol and Zingiber Officinale (Ginger) root extract; (e) squalane; and (f) hyaluronic acid.

[0008] The skincare compositions may further contain a variety of other components. For example, the skincare compositions may further contain one or more cannabinoid selected from the group consisting of A⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), cannabidiolic acid (CBD A), cannabidivarin (CBDV) , tetrahydrocannabivarin (THCV) and combinations thereof. In certain embodiments, the cannabinoid is cannabidiol. Additionally, the skincare compositions may contain caprooyl phytosphingosine and/or caprooyl sphingosine.

[0009] In other embodiments, the skincare compositions also contain one or more of one or more of caprylic/ capric triglyceride, glycerin, glyceryl caprylate, a glycol, ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, a sterol, cetyl alcohol, quercetin, sodium stearoyl glutamate, and glyceryl stearate citrate. The glycerol may be pentylene glycol, hexylene glycol, caprylyl glycol, or combinations thereof. The sterol may be cholesterol. In certain embodiments, the cetyl alcohol is provided as cetostearyl alcohol. In other embodiments, the skincare compositions also contain a sufficient amount of sodium hydroxide so that the skincare composition has a pH between about 5.0 to about 6.5.

[0010] In one embodiment, the skincare composition comprises the following: (a) from about 0.0001% (wt/wt) to about 0.03% (wt/wt) of least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, and combinations thereof;

(b) from about 6.0% (wt/wt) to about 11% (wt/wt) of Helianthus Annuus (sunflower) seed oil;

(c) from about 0.001% (wt/wt) to about 0.01% (wt/wt) of Inula Helenium (elecampane root) extract;

(d) from about 0.1% (wt/wt) to about 0.4% (wt/wt) of bisabolol and from about 0.0008% (wt/wt) to about 0.005% (wt/wt) of Zingiber Officinale (Ginger) root extract;

(e) from 1.5% (wt/wt) to about 4% (wt/wt) of squalane; and

(1) from about 0.005% (wt/wt) to about 0.04% (wt/wt) of hyaluronic acid.

This skincare composition may also optionally include one or more cannabinoid such as, for example, cannabidiol.

[0011] In certain embodiments, the skincare compositions are free of formaldehyde, parabens, phthalates, propylene glycol, sulfates, sulfates, synthetic dyes, and synthetic fragrance. In other embodiments, the skincare compositions are formulated for topical application to keratinous tissue.

[0012] The invention also provides for methods of preventing transepidermal water loss by applying the skincare compositions to the surface of the skin of a subject. The methods of invention may reduce activity of IL- la, TNFa, CO.X-2. and PGE2. In one embodiment, the methods reduce transepidermal water due to atopic dermatitis. The methods may optionally involve cooling the composition prior to application to the skin.

[0013] In certain embodiments, the invention is directed to using a Cannabis extract in a skincare composition m the preparation of a medicament for treating a skin disorder. In certain embodiments, the invention is directed to using the skincare compositions in the manufacture of a medicament for treating atopic dermatitis. Yet another embodiment is a skincare composition having any of the features described above for use in treating atopic dermatitis. An alternative embodiment is use of a skincare composition having any of the features described for treating atopic dermatitis.

[0014] In certain embodiments, the invention is directed to a topical delivery system that may advantageously enhance the delivery of the active components of a Cannabis extract to the skin of the user.

[0015] Other features and advantages of the invention will be apparent from the detailed description and examples that follow. DETAILED DESCRIPTION

[0016] The present disclosure provides skincare compositions that are specifically designed to minimize, reduce, and/or prevent transepidermal water loss. These skincare compositions contain various components including but not limited to ceramides, Helianthus Annuus (sunflower) seed oil, Inula Helenium (elecampane root) extract, bisabolol and Zingiber Officinale (Ginger) root extract, squalane, and hyaluronic acid as well as other optional ingredients including a cannabinoid. The skincare composition may be used to reduce and/or prevent transepidermal water loss. The skincare compositions may be a moisturizer, such a facial moisturizer.

[0017] In certain embodiments, the compositions provide for enhanced delivery of the cannabinoid. In particular, without being bound by theory, it is thought that the combination of the cannabinoid and squalene provides for an improved penetration rate of the cannabinoid (such as e.g. CBD). Furthermore, the compositions are formulated to allow for optimal delivery of the cannabinoid to the epidermis of the skin. Therefore, the compositions of the invention allow for improved efficacy of cannabinoids such as CBD for topical application. By combining the cannabinoid and squalane, the claimed compositions provide for improved delivery of the cannabinoids to the skin, moisturization, brightening and the reduction of the appearance of fine lines and wrinkles.

[0018] The skincare compositions may also be used to treat diseases associated with transepidermal water loss, i.e. elevated transepidermal water loss. Examples of such diseases include, but are not limited to, atopic dermatitis, contact dermatitis, psoriasis, and ichthyosis.

[0019] In addition to reducing transepidermal water loss, the skincare compositions provide further benefits. Such benefits include, but are not limited to, improvement of skin appearance, stress reduction, improved skin texture, reduction of appearance of lines and wrinkles, visible reduction of facial lines and wrinkles, and/or reduction of skin redness. The compositions of the invention may also rebalance the skin, replenish skin barrier moisture and help boost protection from environmental pollutants.

[0020] The skincare compositions of the invention may also maintain the acid mantle, which is a delicate outer layer of skin that keeps skin balanced and working optimally and support the skin’s moisture barrier.

[0021] Each of the individual embodiments described and illustrated herein have discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method may be carried out in the order of events recited or in any other order which is logically possible.

Definitions

[0022] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods, and materials are now described.

[0023] Some of the quantitative expressions given herein are not qualified with the term “about”. It is understood that whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.

[0024] As used herein, the term “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ± 20% or ± 10%, more preferably ± 5%, even more preferably ± 1%, and still more preferably ± 0.1% from the specified value, as such variations are appropriate.

[0025] It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements or use of a “negative” limitation.

[0026] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, mean “including but not limited to”, and are not intended to (and do not) exclude other components.

[0027] The term “subject” means any animal, particularly a mammal, most particularly a human, who will be or has been treated by a method according to an embodiment of the invention. The term “mammal” as used herein, encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs) such as monkeys or apes, humans, etc., more particularly a human.

[0028] As used herein, the term “treat”, “treating”, or “treatment” of any disease, condition, syndrome or disorder refers, in one embodiment, to ameliorating the disease, condition, syndrome or disorder (i.e. slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment, “treat,” “treating”, or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In a further embodiment, “treat”, “treating”, or “treatment” refers to modulating the disease, condition, syndrome or disorder either physically (e.g. stabilization of a discernible symptom), physiologically, (e.g. stabilization of a physical parameter), or both. In yet another embodiment, “treat”, “treating”, or “treatment” refers to preventing or delaying the onset or development or progression of the disease, condition, syndrome, or disorder.

Skincare compositions

[0029] In one embodiment, the invention provides skincare compositions that minimize, reduce, and/or prevent transepidermal water loss. These skincare compositions contain various components including but not limited to ceramides, Helianthus Annuus (sunflower) seed oil, Inula Helenium (elecampane root) extract, bisabolol and Zingiber Officinale (Ginger) root extract, squalane, and hyaluronic acid as well as other optional ingredients.

[0030] One embodiment of the invention is a skincare composition for reducing and/or preventing transepidermal water loss containing at least: one or more ceramide, Helianthus Annuus (sunflower) seed oil, Inula Helenium (elecampane root) extract, bisabolol and Zingiber Officinale (Ginger) root extract, squalane, and hyaluronic acid. The skincare composition may contain additional ingredients. In certain embodiments, squalene may be sugarcane squalene.

[0031] In certain embodiments of the invention, the skincare composition contains: (a) from about 0.0001% (wt/wt) to about 0.03% (wt/wt) of the one or more ceramide; (b) from about 6.0% (wt/wt) to about 11% (wt/wt) of Helianthus Annuus (sunflower) seed oil; (c) from about 0.001% (wt/wt) to about 0.01% (wt/wt) of Inula Helenium (elecampane root) extract; (d) from about 0.1% (wt/wt) to about 0.4% (wt/wt) of bisabolol and from about 0.0008% (wt/wt) to about 0.005% (wt/wt) of Zingiber Officinale (Ginger) root extract; (e) from 1.5% (wt/wt) to about 4% (wt/wt) of squalane; (f) from about 0.005% (wt/wt) to about 0.04% (wt/wt) of hyaluronic acid; and (g) combinations thereof. The composition may also contain deionized water, which may be present in an amount in excess of 50% (wt/wt), alternatively from about 55% (wt/wt) to about 65% (wt/wt).

[0032] In certain embodiments of the invention, the skincare composition contains: (a) from about 0.0001% (wt/wt) to about 0.03% (wt/wt) of the one or more ceramide; (b) from about 6.0% (wt/wt) to about 11% (wt/wt) of Helianthus Annuus (sunflower) seed oil; (c) from about 0.001% (wt/wt) to about 0.01% (wt/wt) of Inula Helenium (elecampane root) extract; (d) from about 0.1% (wt/wt) to about 0.4% (wt/wt) of bisabolol and from about 0.0008% (wt/wt) to about 0.005% (wt/wt) of Zingiber Officinale (Ginger) root extract; (e) from 1.5% (wt/wt) to about 4% (wt/wt) of squalane; and (f) from about 0.005% (wt/wt) to about 0.04% (wt/wt) of hyaluronic acid. The composition may also contain deionized water, which may be present in an amount in excess of 50% (wt/wt), alternatively from about 55% (wt/wt) to about 65% (wt/wt).

[0033] In one embodiment, this skincare composition contains at least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, and combinations thereof. In another alternate embodiment, the skincare composition contains Ceramide NP and Ceramide NS. In yet an alternate embodiment, the skincare composition contains Ceramide NP, Ceramide NS, and/or Ceramide AP. In an alternate embodiment, the skincare composition contains Ceramide NP, Ceramide NS, Ceramide AP, and/or Ceramide EOP. In yet another embodiment, the skincare composition contains Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS.

[0034] In one embodiment, this skincare composition contains at least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, and combinations thereof in a total amount from about 0.0001% (wt/wt) to about 0.003% (wt/wt). In another alternate embodiment, the skincare composition contains Ceramide NP and Ceramide NS. In yet an alternate embodiment, the skincare composition contains Ceramide NP, Ceramide NS, and/or Ceramide AP. In an alternate embodiment, the skincare composition contains Ceramide NP, Ceramide NS, Ceramide AP, and/or Ceramide EOP, each in an amount from about 0.0001% (wt/wt) to about 0.01% (wt/wt). In yet another embodiment, the skincare composition contains Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, each in an amount from about 0.0001% (wt/wt) to about 0.03% (wt/wt).

[0035] In certain embodiments of the invention, the skincare composition comprises a synergistic amount of bisabolol and Zingiber Officinale (Ginger) root extract. In an embodiment, the composition contains bisabolol and Zingiber Officinale (Ginger) root extract in an amount to inhibit IL- la. TNFa, COX-2, and PGE2.

[0036] In one embodiment, the skincare compositions reduce transepidermal water loss. In another embodiment, the skincare compositions prevent transepidermal water loss.

[0037] In certain embodiments, the skincare compositions have a pH between about 5.0 and about 6.5 at a temperature of 25°C.

[0038] The skincare compositions of the invention may further contain one or more cannabinoid. Cannabinoids are a family of compounds found in the cannabis plant. In certain embodiment, the cannabinoid is derived from Cannabis sativa extract. As used herein, the term “cannabinoid” includes cannabinoids that are found in the cannabis plant as well as synthetic derivatives thereof. The skincare composition may advantageously enhance the delivery of the active components of the Cannabis sativa extract (/. e. cannabinoid) to the skin of a user. In one embodiment, the composition contains one or more cannabinoid and sugarcane squalene.

[0039] The prominent compounds among the cannabinoids include but are not limited to Cannabigerolic Acid (CBGA), Cannabigerolic Acid monomethylether (CBGAM), Cannabigerol (CBG), Cannabigerol monomethylether (CBGM), Cannabigerovarinic Acid (CBGV A), Cannabigerovarin (CBGV), Cannabichromenic Acid (CBCA), Cannabichromene (CBC), Cannabichromevarinic Acid (CBCVA), Cannabichromevarin (CBCV), Cannabidiolic Acid (CBDA), Cannabidiol (CBD), Cannabidiol monomethylether (CBDM), Cannabidiol-C4 (CBD-C4), Cannabidivarinic Acid (CBDVA), Cannabi divarin (CBDV), Cannabidiorcol (CBD-C1), Tetrahydrocannabinolic acid A (THCA-A), Tetrahydrocannabinolic acid B (THCA-B), Tetrahydrocannabinolic Acid (THCA), Tetrahydrocannabinol (THC), Tetrahydrocannabinolic acid C4 (THCA-C4), Tetrahydrocannbinol C4 (THC-C4), Tetrahydrocannabivarinic acid (THCVA), Tetrahydrocannabivarin (THCV), Tetrahydrocannabiorcolic acid (THCA-C1), Tetrahydrocannabiorcol (THC-C1), A7-cis-iso-tetrahydrocannabivarin, A8- tetrahydrocannabinolic acid (A8-THCA), Cannabivarinodiolic (CBNDVA), Cannabivarinodiol (CBNDV), A8-tetrahydrocannabinol (A8-THC), A9- tetrahydrocannabinol (A9-THC), Cannabicyclolic acid (CBLA), Cannabicyclol (CBL), Cannabicyclovarin (CBLV), Cannabielsoic acid A (CBEA-A), Cannabielsoic acid B (CBEA-B), Cannabielsoin (CBE), Cannabivarinselsoin (CBEV), Cannabivarinselsoinic Acid (CBEV A), Cannabielsoic Acid (CBEA), Cannabielvarinsoin (CBLV), Cannabielvarinsoinic Acid (CBLV A), Cannabinolic acid (CBNA), Cannabinol (CBN), Cannabivarinic Acid (CBNVA), Cannabinol methylether (CBNM), Cannabinol-C4 (CBN- C4), Cannabivarin (CBV), Cannabino-C2 (CBN-C2), Cannabiorcol (CBN-C1), Cannabinodiol (CBND), Cannabinodiolic Acid (CBNDA), Cannabinodivarin (CBDV), Cannabitriol (CBT), 10-Ethoxy-9-hydroxy-A6a-tetrahydrocannabinol, 8,9-Dihydroxy- A6a(10a)-tetrahydrocannabinol (8,9-Di-OH-CBT-C5), Cannabitriolvarin (CBTV), Ethoxy- cannabitriolvarin (CBTVE), Dehydrocannabifuran (DCBF), Cannbifuran (CBF), Cannabichromanon (CBCN), Cannabicitran (CBT), 10-Oxo-A6a(10a)-tetrahydrocannabinol (OTHC), A9-cis-tetrahydrocannabinoi (cis-THC), Cannabiripsol (CBR), 3,4,5,6-tetrahydro- 7 -hydroxy-alpha-alpha-2 -trimethyl-9-n-propyl-2,6-methano-2H- 1 -benzoxocin-5-methanol (OH-iso-HHCV), and Trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC).. Currently, there are about 144 known compounds in the cannabinoid family. See Aizpuora-Olaizala, Journal of Natural Products. 79 (2): 324-31 (2016) (the disclosure of which is incorporated as it pertains to cannabinoids).

[0040] The IUPAC nomenclature of THC is (-)-(6aR,10aR)-6,6,9-trimethyl-3- pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-l-ol. CBD's IUPAC nomenclature is 2- ((lS,6S)-3-methyl-6-(prop-l-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-l,3-diol). CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. CBG has the IUPAC nomenclature of 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5- pentylbenzene-l,3-diol. CBD is a natural constituent in hemp plants, as well as other plants in the cannabis genus.

[0041] Accordingly, in one embodiment, the skincare composition comprises one more or more cannabinoid selected from the group consisting of A⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), and combinations thereof. In one embodiment, the composition comprises cannabidiol. The cannabinoid, such as e.g. cannabidiol, may be derived from Cannabis sativa. In certain embodiments, where the compositions contain delta-9 tetrahydrocannabinol, the composition has a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.

[0042] In certain embodiments, the skincare compositions also contain an effective amount of Cannabis sativa extract, which is used to provide the one or more cannabinoid. The extract may be derived from the flower, leaf, and stem of a Cannabis sativa plant, such as hemp plant. Such extract is rich in cannabidiol and is generally known as CBD oil. Preferably, the Cannabis sativa extract has a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis. In certain embodiments, the composition contains from about 0.3% (wt/wt) to about 0.7% (wt/wt) of Cannabis sativa extract. It has been found that the formulation with an effective amount of Cannabis sativa extract provide additional benefits for transepidermal water lost prevention.

[0043] The Cannabis extract may also comprise non-cannabinoid compounds, which typically includes a terpene fraction, l.e. terpenes and terpenoids. Tn some embodiments, the Cannabis extract comprises a terpene fraction in an amount of less than 20% by weight, for example, less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% by weight of the extract. In some embodiments, the Cannabis extract may comprise terpene and terpenoid compounds in an amount of more than 0.001% by weight of the extract, for example, more than 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, or 1% of the total weight of the extract. In some embodiments, the Cannabis extract comprises about 0.001% to about 20% by weight of terpene and terpenoid compounds, for example, about 0.001% to about 15% by weight, about 0.001% to about 10% by weight, about 0.001% to about 6% by weight or about 0.001% to about 5% by weight of the composition.

[0044] Typically, the terpene fraction in the Cannabis plant material used to form the extract may have a different terpene/terpenoid profile than the terpene profile of the final extract, both in terms of the amounts of specific compounds in the terpene fraction and the weight of the terpene fraction relative to the other components. For example, a Cannabis flower may comprise about 20% by weight cannabinoids and about 3% by weight terpenes. Following extraction and concentration (/. e. removal of the extractant), the amount of cannabinoids may increase to an amount of about 50-90% by weight and the terpene fraction may amount to about 0.1-6% by weight of the Cannabis extract. This typical scenario shows that while the cannabinoids are concentrated when the extractant is removed, the relative amount of the terpene fraction is reduced, likely due to the volatility of many of the terpenes/terpenoids present in the terpene fraction. Therefore, the profile of the terpene fraction present in the Cannabis extract is significantly different from the profile of the terpene fraction that exists in Nature.

[0045] A variety of terpenes and terpenoids have also been identified in Cannabis extracts, including monoterpenes, monoterpenoids, sesquiterpenes and sesquiterpenoids. For example, the following terpenes and terpenoids have been identified in Cannabis extracts: Alloaromadendrene, allyl hexanoate, benzaldehyde, (Z)-a-cis-bergamotene, (Z)-a-trans- bergamotene, tybisabolol, epi-a-bisabolol, p-bisabolene, borneol (camphol), cis-y- bisabolene, borneol acetate (bornyl acetate), a-cadinene, camphene, camphor, cis-carveol, caryophyllene (P-caiyophyUene), a-humulene (a-caryophyllene), y-cadinene, A-3-carene, caryophyllene oxide, 1,8-cineole, citral A, citral B, cinnameldehyde, a-copaene (aglaiene), y-curcumene, P-cymene, P-elemene, y-elemene, ethyl decdienoate, ethyl maltol, ethyl propionate, ethylvamllm, eucalyptol, a-eudesmol, p-eudesmol, y-eudesmol, eugenol, cis-P-famesene ((Z)-P-farnesene), trans-a-famesene, trans-p-famesene, trans-y-bisabolene, fenchone, fenchol (norbomanol, £-fencho1), geraniol, a-guaiene, guaiol, methyl anthranilate, methyl salicylate, 2-methyl— l~heptanone, 3-meihyl-4-heptanone, hexyl acetate, ipsdienol, isoamyl acetate, iemenol, limonene, d-limonene (limonene), Imolool (linalyl alcohol, P-linolool), a-longipinene, menthol, y-muurolene, myrcene (p-myrcene), nerolidol, trans- nerolidol, nerol, P-ocimene (cis-ochnene), octyl acetate, a-phellandrene, phytol, a-pinene (2 -pinene), p-pmene, pulegone, sabmene, cis-sabmene hydrate (cis-thujanol), p-selinene, a-selinene, y-terpinene, terpinolene (isoterpine), terpineol (a-terpineol), terpineol-4-ol, a-terpinene (terpilene), a-fhujene (origanene), vanillin, viridiflorene (ledene), and a-ylange.

[0046] In certain embodiments of the invention, the skincare compositions may also comprise hemp oil, also known as hemp seed oil, which is obtained by pressing hemp seeds.

[0047] In certain embodiments of the invention, the skincare compositions may further comprise caprooyl phytosphingosine and/or caprooyl sphingosine. Alternatively, the skincare compositions may further comprise one or more of caprylic/ capric triglyceride, glycerin, glyceryl caprylate, a glycol, ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, a sterol, cetyl alcohol, quercetin, sodium stearoyl glutamate, glyceryl stearate citrate, and combinations thereof. The glycol may be pentylene glycol, hexylene glycol, caprylyl glycol, or combinations thereof. In certain embodiments, the sterol is cholesterol. The cetyl alcohol may be provided as cetostearyl alcohol.

[0048] In other embodiments, the skincare compositions may further comprise one or more of caprooyl phytosphingosine and/or caprooyl sphingosine, caprylic/capric triglyceride, glycerin, glyceryl caprylate, a glycol (e.g. pentylene glycol, hexylene glycol, caprylyl glycol, or combinations thereof), ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, a sterol (e.g. cholesterol), cetyl alcohol, quercetin, sodium stearoyl glutamate, and glyceryl stearate citrate, and combinations thereof.

[0049] In certain embodiments, the skincare compositions also contain: (i) caprooyl phytosphingosine and/or caprooyl sphingosine; (ii) pentylene glycol, hexylene glycol, and caprylyl glycol; and (iii) caprylic/capric triglyceride, glycerin, glyceryl caprylate, ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, cholesterol, cetyl alcohol, quercetin, sodium stearoyl glutamate, and glyceryl stearate citrate.

[0050] In another embodiment of the invention, the composition contains: from about 0.0001% (wt/wt) to about 0.002% (wt/wt) of caprooyl phytosphingosine and/or caprooyl sphingosine; from about 1.0% (wt/wt) to about 1.3% (wt/wt) of pentylene glycol; from about 0.05% (wt/wt) to about 0.2% (wt/wt) hexylene glycol; and from about 0.05% (wt/wt) to about 0.5% (wt/wt) of caprylyl glycol; from about 7.0% (wt/wt) to about 8.7% (wt/wt) of caprylic/ capric triglyceride; from about 0.01% (wt/wt) to about 0.1% (wt/wt) of ceteareth-25, from about 0.05% (wt/wt) to about 0.2% (wt/wt) of ethylhexylglycerin, from about 0.3% (wt/wt) to about 1.0% (wt/wt) of phenoxyethanol; from about 0.001% (wt/wt) to about 0.01% (wt/wt) of behenic acid; from about 0.1% (wt/wt) to about 0.8% (wt/wt) of carbomer; from about 0.0005% (wt/wt) to about 0.003% (wt/wt) of quercetin; and combinations thereof. The composition may also contain from about 2% (wt/wt) to about 4% (wt/wt) of cetostearyl alcohol.

[0051] In certain embodiments, the skincare compositions of the invention contain a sufficient amount of sodium hydroxide so that the compositions have a pH between about 5.0 and about 6.5 at a temperature of 25°C. For example, the composition may contain from about 0.005% (wt/wt) to about 0.2 % (wt/wt) of sodium hydroxide.

[0052] The skincare compositions are formulated for topical application to keratinous tissue. In certain embodiments, the skincare compositions of the invention may be formulated to as an eye cream. In other embodiments, the skin compositions may be formulated as a serum. In alternate embodiments, the skincare compositions may be formulated as a moisturizer. In other embodiments, squalene may be used in place of squalane.

[0053] In one embodiment of the invention, the skincare composition has at least the following components: (a) one or more of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, and combinations thereof; (b) Helianthus Annuus (sunflower) seed oil; (c) Inula Helenium (elecampane root) extract; (d) bisabolol and Zingiber Officinale (Ginger) root extract; (e) squalane; (1) hyaluronic acid; (g) caprooyl phytosphingosine and/or caprooyl sphingosine; (h) pentylene glycol, hexylene glycol, and caprylyl glycol; (i) caprylic/ capric triglyceride, glycerin, glyceryl caprylate, a glycol, ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, cholesterol, cetyl alcohol, cetearyl alcohol, quercetin, sodium stearoyl glutamate, and glyceryl stearate citrate; and (j) a cannabinoid such as e.g. cannabidiol. [0054] In another embodiment, the skincare composition comprises:

(a) from about 0.0001% (wt/wt) to about 0.03% (wt/wt) of ceramides (such as e.g. each of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS);

(e) from 1.5% (wt/wt) to about 4% (wt/wt) of squalane;

(1) from about 0.005% (wt/wt) to about 0.04% (wt/wt) of hyaluronic acid;

(g) one or more cannabinoid, such as, for example, cannabidiol or from about 0.3% (wt/wt) to about 0.7% (wt/wt) of Cannabis sativa extract;

(h) from about 0.0001% (wt/wt) to about 0.002% (wt/wt) of caprooyl phytosphingosine and/or caprooyl sphingosine;

(i) from about 1.0% (wt/wt) to about 1.3% (wt/wt) of pentylene glycol, from about 0.05% (wt/wt) to about 0.2% (wt/wt) hexylene glycol, and from about 0.05% (wt/wt) to about 0.5% (wt/wt) of caprylyl glycol; and

(j) from about 7.0% (wt/wt) to about 8.7% (wt/wt) of caprylic/capric triglyceride, from about 3.5% (wt/wt) to about 5.5% (wt/wt) of glycerin, from about 2.0% (wt/wt) to about 3.5% of glyceryl caprylate, from about 0.01% (wt/wt) to about 0.1% (wt/wt) of ceteareth-25, from about 0.05% (wt/wt) to about 0.2% (wt/wt) of ethylhexylglycerin, from about 0.3% (wt/wt) to about 1.0% (wt/wt) of phenoxyethanol, from about 0.001% (wt/wt) to about 0.01% (wt/wt) of behenic acid, from about 0.1% (wt/wt) to about 0.8% (wt/wt) of carbomer, from about 0.0001% (wt/wt) to about 0.01% (wt/wt) of cholesterol, from about 0.005% (wt/wt) to about 0.1% (wt/wt) of cetyl alcohol, from about 4.0% to about 7.0% of cetearyl alcohol; from about 0.0005% (wt/wt) to about 0.003% (wt/wt) of quercetin, from about 0.1% (wt/wt) to about 2.0% (wt/wt) of sodium stearoyl glutamate, and from about 0.05% (wt/wt) to about 0.2% (wt/wt) of glyceryl stearate citrate. [0055] The skincare compositions also contain water (e.g. deionized water). In certain embodiments, the skincare compositions contain more than 50% (wt/wt) of water. In other embodiments, the compositions contain from about 55% (wt/wt) and about 70% (wt/wt) of water.

[0056] In certain embodiments of the invention, the skincare composition may be assembled by choosing one embodiment of Base Component A, one embodiment of Optional Component B, and one embodiment of Optional Component C. The various embodiments of Base Component A, Optional Component B and Optional Component C are shown in the Tables below. In certain embodiments, Optional Component B may be omitted. Accordingly, exemplary embodiments of the invention include the following skincare compositions:

[0057] Each of these various embodiments of the compositions may contain a sufficient amount of sodium hydroxide so that the composition has a pH between about 5.0 and about 6.5 at a temperature of 25°C. In certain embodiments, where the compositions formulated from one embodiment of Base Component A, one embodiment of Optional Component B, and one embodiment of Optional Component C contain delta-9 tetrahydrocannabinol, the composition has a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis. Furthermore, each of the ingredients of Base Component A, Optional Component B, and/or Optional Component C may be used in the amounts described above. In certain embodiments, the cetyl alcohol is cetostearyl alcohol.

[0058] Tables 1-5 show exemplary skincare compositions according to certain embodiments of the invention. These exemplary skincare compositions may have a pH between about 5.0 and about 6.5 at a temperature of 25°C. Persons skilled in the art will recognize that certain components can be replaced by other components with similar function. In most cases, these can be used interchangeably and persons skilled in the art of cosmetic and cosmeceutical formulations can adjust amounts to achieve a desired consistency and feel in the product. However, the exemplary skincare compositions below are thought to provide particularly desirable results, including but not limited to reduced transepidermal water loss and increased skin surface hydration.

[0059] In one embodiment of the invention, the skincare composition comprises embodiment 1 shown in the Example 1 below. In another embodiment, the skincare composition comprises embodiment 2 shown in Example 1 below. In yet another embodiment, the skincare composition contains water (Aqua), Helianthus Annuus (Sunflower) Seed Oil, capry lie/ capric triglyceride, cetearyl alcohol, glycerin, squalane, glyceryl caprylate, pentylene glycol, hemp oil, Inula Helenium extract, Zingiber Officinale (ginger) root extract, bisabolol, hyaluronic acid, Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, Ceramide EOS, caprooyl phytosphingosine, caprooyl sphingosine, sodium stearoyl glutamate, glyceryl stearate citrate, quercetin, Ceteareth-25, behenic acid, cetyl alcohol, carbomer, cholesterol, sodium hydroxide, hexylene glycol, caprylyl glycol, ethylhexylglycerin, and phenoxyethanol. In each of these embodiments, the components may be used in the amounts described herein.

[0060] In each of the embodiments of the invention, the skincare composition is preferably free of one or more of formaldehyde, parabens, phthalates, propylene glycol, sulfates, synthetic dyes, synthetic fragrance, and combinations thereof. Alternatively, in each of the embodiments of the invention, the skincare composition is preferably free of each of formaldehyde, parabens, phthalates, propylene glycol, sulfates, synthetic dyes, and synthetic fragrance.

Use of skincare compositions

[0061] In another aspect, the present invention provides for use of the skincare composition of the invention to prevent and/or reduce transepidermal water loss. In one embodiment, the skincare compositions are used to prevent transepidermal water loss. In another embodiment, the skincare compositions are used to reduce transepidermal water loss.

[0062] In an alternate embodiment, the skincare compositions may be used to treat a disease or condition associated with transepidermal water loss, such as for example atopic dermatitis (AD), contact dermatitis, psoriasis, and ichthyosis.

[0063] In one embodiment, the skincare compositions may be used to treat atopic dermatitis. In another embodiment, the skincare compositions may be used to treat contact dermatitis. In yet another embodiment, the skincare compositions may be used to treat psoriasis. In an alternate embodiment, the skincare compositions may be used to treat ichthyosis.

[0064] Accordingly, one embodiment of the invention is use of a skincare composition of the instant disclosure in the manufacture of a medicament for treating atopic dermatitis. Another embodiment of the invention is a skincare composition of the instant disclosure for use in treating atopic dermatitis. In alternate embodiment of the invention is use of a skincare composition of the instant disclosure for treating atopic dermatitis.

[0065] Yet another embodiment of the invention is use of a skincare composition of the instant disclosure in the manufacture of a medicament for treating contact dermatitis, psoriasis, and/or ichthyosis. Another embodiment is a skincare composition of the instant disclosure for use in treating contact dermatitis, psoriasis, and/or ichthyosis. Yet another alternate embodiment is use of a skincare composition of the instant disclosure for treating contact dermatitis, psoriasis, and/or ichthyosis.

[0066] Additionally, one embodiment of the invention is use of a skincare composition of the instant disclosure in the manufacture of a medicament for reducing transepidermal water loss. Another embodiment is a skincare composition for use in reducing transepidermal water loss. An alternate embodiment of the invention is use of a skincare composition of the instant disclosure for reducing transepidermal water loss.

[0067] Another embodiment of the invention is a method of preventing and/or reducing transepidermal water loss comprising applying the skincare composition of the instant disclosure to the surface of the skin of a subject, i.e. the skincare compositions are topically applied to skin. In one embodiment, the method prevents transepidermal water loss. In another embodiment, the method reduces transepidermal water loss. The subject may preferably be a human. In one embodiment, the subject may between 24 and 64 years of age. The skincare composition may be applied to the face, decolletage, or both. In certain embodiments, multiple applications daily of the composition may be desirable. Accordingly, in one embodiment, the methods, the skincare composition is applied twice daily. The method may also include applying a CBD oil or a Cannabis sativa extract after application of the skincare composition. In some embodiments, the method also includes coolmg the composition prior to application to the skin.

[0068] In certain embodiments, the method reduces the activity of IL- la, TNFa, CO.X-2, and PGE2. In other embodiments, the method inhibits the activity of IL- la, TNFa, COX-2, and PGE2. The method may also reduce transepidermal water due to atopic dermatitis.

[0069] Another embodiment of the invention is a method of treating atopic dermatitis, which is also known as eczema, comprising applying a skincare composition of the instant disclosure to the surface of the skin of a subject. In certain embodiments, the skincare composition is applied to the surface of the skin where the atopic dermatitis is found. In preferred embodiments, the subject is human. In certain embodiments, the skincare composition is applied to the face, decolletage, or both. In one embodiment, the skincare composition is applied twice daily. In other embodiments, multiple daily applications may be used. The same method steps may be employed to use the skincare composition to treat contact dermatitis, psoriasis, or ichthyosis.

Kits

[0070] In another embodiment, the invention is directed to kit containing a skincare composition for preventing transepidermal water loss as disclosed herein. The kit may optionally include an applicator and/or instructions for use. In one embodiment, the kit contains a skincare composition disclosed herein and a solution containing cannabinoid such as cannabidiol. The solution containing the cannabidiol may be an oil. In certain embodiments, the solution is a Cannabis sativa extract.

Methods of making the skincare compositions

[0071] Other embodiments of the invention are directed to methods of making the skincare compositions of the instant disclosure. The skincare compositions are generated by step-wise addition using the general process described below.

[0072] In one embodiment, the method of generating the skincare compositions of the invention comprises: adding hyaluronic acid to water and heating the mixture a temperature of about 70 °C to about 80 °C; adding Helianthus Annuus (Sunflower) Seed Oil and cooling by about 5 °C; optionally adding the Cannabinoid in Helianthus Annuus (Sunflower) Seed Oil and cooling by about 5 °C; adding one or more ceramide; adding Bisabolol and Zingiber Officinale (Ginger) Root Extract; and adding the Inula Helenium Extract. The resulting skincare composition is then cooled down to about 35°C and packaged. Each step of adding may including mixing.

[0073] Step 1 : To generate the skincare compositions deionized water is provided to which hyaluronic acid is added first and if present carbomer. Theses ingredients are fixed until completely uniform; then the solution is heated to a temperature of about 70 °C to about 80 °C. Step 1 may be carried out in a processing tank.

[0074] Step 2: To the extent present, to the solution generated in Step 1, glycerin and pentylene glycol are added. After each addition, the solution is mixed well.

[0075] Step 3: One or more capry lie/ capric triglyceride, squalane, Helianthus Annuus (Sunflower) Seed Oil, cetearyl alcohol, glyceryl caprylate, and glyceryl stearate citrate, and combinations thereof are separately mixed together, heated to a temperature of about 75 °C to about 80 °C, and mixed until uniform. The temperature is maintained, and the resulting solution is added to the solution obtained in Step 2.

[0076] Step 4: Separately sodium hydroxide (such as e.g. caustic soda) is dissolved in deionized water, added the solution obtained in Step 3, and mixed until uniform. The resulting mixture is then cooled by about 5 °C.

[0077] Step 5: Where present a mixture of phenoxyethanol, caprylyl glycol, hexylene glycol, and ethylhexylglycerin is added to the mixture generated in Step 4. The resulting solution is the mixed until uniform and cooled by about an additional 5 °C.

[0078] Step 6: Additional Helianthus Annuus (Sunflower) Seed Oil and the cannabinoid (cannabidiol or Cannabis sativa extract) are heated to a temperature of about 65°C and mixed until uniform. The resulting mixture is then added to the mixture of Step 6, mixed until uniform and cooled by about 5 °C.

[0079] In embodiments where the composition contains a cannabinoid (e.g. cannabidiol) or a Cannabis sativa extract, the cannabinoid (e.g. cannabidiol) or a Cannabis sativa extract are heated until all the crystals are dissolved prior to use. Such heating may be achieved to a temperature of about 70 °C for a suitable period of time.

[0080] Step 7: To the resulting mixture in Step 6, the one or more ceramide is then added to the mixture of Step 6, the resulting mixture is mixed until uniform and further cooled by about 5 °C. In certain embodiments, a solution containing the following as added to the mixture of Step 6: Water (Aqua), Ceteareth-25, Glycerin, Cetyl Alcohol, Phenoxyethanol, Behenic Acid, Cholesterol, Ceramide NP, Ethylhexylglycerin, Ceramide NS, Ceramide AP, Ceramide EOP, Ceramide EOS, Caprooyl Phylosphingosine, Caprooyl Sphingosine, Tocopherol, Ascorbyl Palmitate.

[0081] Step 8: Bisabolol and Zingiber Officinale (Ginger) Root Extract is added to the mixture of Step 7 followed by the addition of the Inula Helenium extract. The resulting solution is mixed, and the temperature is maintained at a temperature of about 40°C to about 45°C.

[0082] Step 9: Where present, pentylene glycol and quercetin are mixed together until uniform and added to mixture obtain in Step 8. Mixing and cooling is continued until the mixture, i.e. the skincare composition, has reached a temperature of about 35°C. Afterwards, the skincare composition may be packaged.

[0083] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working example, therefore, specifically points out the preferred embodiments of the present invention and is not to be construed as limiting in any way the remainder of the disclosure.

Examples

Example 1: Assessment of transepidermal water loss by composition of the invention

[0084] A clinical study was conducted to assess the transepidermal water loss by an embodiment of the compositions of the invention. Specifically, the clinical study used the skincare composition of embodiment 1 shown below.

Objectives

[0085] The primary objective of the clinical study was to assess changes in hydration, barrier function, and pH of facial skin following one application in the laboratory and following two weeks of twice daily use of a moisturization product. The secondary objective was to obtain consumer perceptions of the test product following two weeks of twice daily use.

Study Design

[0086] Thirty -five subjects were enrolled in this clinical study to assess changes in hydration, barrier function, and pH of facial skin following one application in the laboratory and following two weeks of twice daily use of a moisturization product, and to obtain consumer perceptions of the test product following two weeks of twice daily use. Study evaluations included Comeometer measurements, transepidermal water loss (TEWL) measurements, pH measurements, and consumer perception questionnaires.

[0087] Product use instructions: Subjects used non-moisturizing soap during the conditioning phase and for the duration of the study. The test material instructions were to apply a pea-sized amount to face after cleansing both morning and night.

[0088] Blinding: Subjects were blinded to the name of the test material. The investigatory staff was not blinded. Test materials were labeled with unique study identification and panel codes and subject numbers upon receipt of the test material.

[0089] Subjects: A total of 35 female subjects, ranging in age from 24 to 65 years, who met all the inclusion criteria and none of the exclusion criteria as outlined in the clinical study protocol, were selected for study participation.

[0090] Protocol Deviations and Adverse Events: No protocol deviations occurred over the duration of the study. No adverse events were reported over the duration of the study.

Results

[0091] Completed and discontinued subjects: A total of 33 subjects completed the study. One subject was discontinued for non-compliance. One subject was lost to follow up.

[0092] Corneometer: A Comeometer was used to assess the hydration level of the superficial layers of the skin (stratum comeum) via measurement of skin dielectric properties. Comeometer measurements were conducted at baseline (prior to application), 30 minutes post-application, 1 hour post-application, and at the end of the two week study. A statistical summary table of the Comeometer measurements is shown in Table 1-1.

[0093] Vapometer (TEWL): A VapoMeter was used to assess transepidermal water loss (TEWL). Vapometer measurements were conducted at baseline (prior to application), 30 minutes post-application, 1 hour post-application, and at the end of the two week study. A statistical summary table of the Vapometer measurements is shown in Table 1-2.

[0094] Skin pH: The skin pH was also measured. Skin pH measurements were conducted at baseline (prior to application), 30 minutes post-application, 1 hour postapplication, and at the end of the two week study. A statistical summary table of the pH measurements is shown in Table 1-3. A significant change at 30 Minutes Post-Application was observed but deemed not to be an improvement.

[0095] In addition, a consumer perception survey was conducted at the end of the two week study. The consumer perception questionnaire frequency and statistical summary are shown in Table 1-4 below.

Conclusion

[0096] Corneometer: Under the conditions of this study and in this test population, the test material, a composition of Embodiment 1, was found to provide a statistically significant improvement in the Corneometer measurements/skin surface hydration (increase in hydration units) after 30 Minutes Post- Application, 1 Hour PostApplication and 2 Weeks of twice daily test material use, when compared to baseline.

[0097] Vapometer: Under the conditions of this study and in this test population, the test material, a composition of Embodiment 1, was found to provide a significant decrease in the TEWL (trans-epidermal water loss) readings after 30 Minutes PostApplication, 1 Hour Post-Application and 2 Weeks of twice daily test material use, when compared to baseline indicating an improvement in the skin barrier function at those timepoints.

[0098] pH Meter: Under the conditions of this study and in this test population, the test material, a composition of Embodiment 1, showed a significant increase in the pH readings at the 30 minutes post application time-point compared to baseline. However, there was no change in the pH readings after one hour and two weeks of product use compared to baseline.

[0099] Consumer Perception Questionnaire: Under the conditions of this study and in this test population, the test material, a composition of Embodiment 1, elicited statistically favorable responses for 19 out of 19 consumer perception questions.

[0100] Thus, Example 1 confirms that a composition of Embodiment 1 reduces transepidermal water loss as well as increasing skin surface hydration.

Numbered Embodiments of the Invention

[0101] Exemplary numbered embodiments of the invention are shown below:

1. A skincare composition for preventing transepidermal water loss comprising:

(a) at least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, or Ceramide EOS, and combinations thereof;

(b) Helianthus Annuus (sunflower) seed oil; (c) Inula Helenium (elecampane root) extract;

(d) bisabolol and Zingiber Officinale (Ginger) root extract;

(e) squalane; and

(f) hyaluronic acid.

2. The skincare composition of embodiment 1, wherein the skincare composition further comprises one or more cannabinoid selected from the group consisting of A⁹- tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), cannabidiolic acid (CBD A), cannabidivarin (CBDV) , tetrahydrocannabivarin (THCV) and combinations thereof.

3. The skincare composition of embodiment 2, wherein the cannabinoid is cannabidiol.

4. The skincare composition of any one of embodiments 1-3, wherein the skincare composition further comprises caprooyl phytosphingosine and/or caprooyl sphingosine.

5. The skincare composition of any one of embodiments 1-4, wherein the skincare composition further comprises one or more of caprylic/ capric triglyceride, glycerin, glyceryl caprylate, a glycol, ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, a sterol, cetyl alcohol, cetearyl alcohol, quercetin, sodium stearoyl glutamate, and glyceryl stearate citrate.

6. The skincare composition of embodiment 5, wherein the glycol is pentylene glycol, hexylene glycol, caprylyl glycol, or combinations thereof.

7. The skincare composition of embodiment 5 or 6, wherein the sterol is cholesterol.

8. The skincare composition of any one of embodiments 5-7, wherein the composition comprises Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS.

9. The skincare composition of any one of embodiments 1-8, wherein the skincare composition has a pH between about 5.0. to about 6.5.

10. The skincare composition of any one of embodiments 1-8, wherein the skincare composition further comprises a sufficient amount of sodium hydroxide so that the skincare composition has a pH between about 5.0. to about 6.5.

11. The skincare composition of any one of embodiments 1-10, wherein the skincare composition comprises: (a) from about 0.0001% (wt/wt) to about 0.03% (wt/wt) of least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, and combinations thereof;

(e) from 1.5% (wt/wt) to about 4% (wt/wt) of squalane; and

(1) from about 0.005% (wt/wt) to about 0.04% (wt/wt) of hyaluronic acid.

12. The skincare composition of any one of embodiments 1-11, wherein the skincare composition is free of formaldehyde, parabens, phthalates, propylene glycol, sulfates, synthetic dyes, and synthetic fragrance.

13. The skincare composition of any one of embodiments 1-12, wherein the skincare composition is formulated for topical application to keratinous tissue.

14. A method of preventing or reducing transepidermal water loss comprising applying the skincare composition of any one of embodiments 1-13 to the surface of the skin of a subject.

15. The method of embodiment 14, wherein the method reduces the activity of IL- la, TNFa, Cl >'< • 2. and PGE2.

16. The method of embodiment 14 or 15, wherein the method reduces transepidermal water due to atopic dermatitis.

17. The method of any one of embodiments 14-17. further comprising cooling the composition prior to application to the skin.

18. Use of a skincare composition of any one of embodiments 1-13in the manufacture of a medicament for treating atopic dermatitis.

19. A skincare composition of any one of embodiments 1-13 for use in treating atopic dermatitis. 20. Use of a skincare composition of any one of embodiments 1-13 for treating atopic dermatitis. While the invention has been described and illustrated herein by references to various specific materials, procedures, and examples, it is understood that the invention is not restricted to the particular combinations of material and procedures selected for that purpose. Numerous variations of such details can be implied as will be appreciated by those skilled in the art. It is intended that the specification and examples be considered as exemplary, only, with the true scope and spirit of the invention being indicated by the following claims. All references, patents, and patent applications referred to in this application are herein incorporated by reference in their entirety.

Claims

CLAIMS What is claimed:

1. A skincare composition for preventing transepi dermal water loss comprising:

(a) at least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, or Ceramide EOS;

(b) Helianthus Annuus (sunflower) seed oil;

(c) Inula Helenium (elecampane root) extract;

(d) bisabolol and Zingiber Officinale (Ginger) root extract;

(e) squalane; and

(f) hyaluronic acid.

2. The skincare composition of claim 1, wherein the skincare composition further comprises one or more cannabinoid selected from the group consisting of A⁹- tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), cannabidiolic acid (CBD A), cannabidivarin (CBDV) , tetrahydrocannabivarin (THCV) and combinations thereof.

3. The skincare composition of claims 1 or 2, wherein the cannabinoid is cannabidiol.

4. The skincare composition of any one of claims 1-3, wherein the skincare composition further comprises caprooyl phytosphingosine and/or caprooyl sphingosine.

5. The skincare composition of any one of claim 1-4, wherein the skincare composition further comprises one or more of caprylic/ capric triglyceride, glycerin, glyceryl caprylate, a glycol, ceteareth-25, ethylhexylglycerin, phenoxyethanol, behenic acid, carbomer, a sterol, cetyl alcohol, cetearyl alcohol, quercetin, sodium stearoyl glutamate, and glyceryl stearate citrate.

6. The skincare composition of claim 5, wherein the glycol is pentylene glycol, hexylene glycol, caprylyl glycol, or combinations thereof.

7. The skincare composition of claim 5, wherein the sterol is cholesterol.

8. The skincare composition of any one of claims 1-7, wherein the composition comprises Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS.

9. The skincare composition of any one of claims 1-8, wherein the skincare composition has a pH between about 5.0 to about 6.5.

10. The skincare composition of claim 1 , wherein the skincare composition further comprises a sufficient amount of sodium hydroxide so that the skincare composition has a pH between about 5.0 to about 6.5.

11. The skincare composition of claim 1, wherein the skincare composition comprises:

(a) from about 0.0001% (wt/wt) to about 0.03% (wt/wt) of least one of Ceramide NP, Ceramide NS, Ceramide AP, Ceramide EOP, and Ceramide EOS, and combinations thereof;

(e) from 1.5% (wt/wt) to about 4% (wt/wt) of squalane; and

(f) from about 0.005% (wt/wt) to about 0.04% (wt/wt) of hyaluronic acid.

12. The skincare composition of any one of claims 1-11, wherein the skincare composition is free of formaldehyde, parabens, phthalates, propylene glycol, sulfates, synthetic dyes, and synthetic fragrance.

13. The skincare composition of any one of claims 1-12, wherein the skincare composition is formulated for topical application to keratinous tissue.

14. A method of reducing transepidermal water loss comprising applying the skincare composition of any one of claims 1-13 to the surface of the skin of a subject.

15. The method of claim 14, wherein the method reduces the activity of IL-la, TNFa, CO.X-2, and PGE2.

16. The method of claim 14. wherein the method reduces transepidermal water due to atopic dermatitis.

17. The method of claim 14, further comprising cooling the composition prior to application to the skin.

18. Use of a skincare composition of any one of claims 1-13 in the manufacture of a medicament for treating atopic dermatitis.

19. A skincare composition of any one of claims 1-13 for use in treating atopic dermatitis.

20. Use of a skincare composition of any one of claims 1-13 for treating atopic dermatitis.